ASCO 2022

REVIEW UroToday

Viewing 1-20 of 142 articles

ASCO 2022: Association of RB1 Mutational Status with Overall Genomic Landscape in Neuroendocrine Prostate Cancer (NEPC)

ASCO 2022: Circulating Tumour Cells (CTCs) and PSMA PET Correlates in the Phase I PRINCE Trial of 177Lu-PSMA-617 plus Pembrolizumab for Metastatic Castration Resistant Prostate Cancer (mCRPC)

ASCO 2022: A Randomized Phase Ib/II Study of Intermittent Androgen Deprivation Therapy Plus Nivolumab With or Without Interleukin-8 Blockade in Men With Hormone-Sensitive Prostate Cancer (MAGIC-8)

ASCO 2022: T-cell Redirection in Advanced Prostate Cancer to Prevent Cancer Progression and Death - Discussion

ASCO 2022: Future Targets for Cellular Therapy in Prostate Cancer

ASCO 2022: CAR T for Prostate Cancer: Current Strategies to Improve Efficacy

ASCO 2022: T-Cell Engagers for Prostate Cancer: Efficacy and Toxicity Management

ASCO 2022: Genomic Alterations and Evolution in Patients With Prostate Cancer With Histologic Evidence of Neuroendocrine Differentiation

ASCO 2022: Bone Biomarkers and Overall Survival in Men with Advanced HSPC: Results from SWOG S1216, a Phase III Trial of ADT +/- Orteronel

ASCO 2022: BRCAAway: A Randomized Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with mCRPC with DNA Repair Defects

ASCO 2022: A Phase 2 Randomized Study of Oral Docetaxel plus Ritonavir (ModraDoc006/r) in Patients with mCRPC

ASCO 2022: Defining More Precisely the Effects of Docetaxel plus ADT for Men with mHSPC: Meta-Analysis of Individual Participant Data from Randomized Trials

ASCO 2022: Discussant: AR and PARP: Partners in Crime

ASCO 2022: Discussant: Familiar Faces and New Directions for Prostate Cancer

ASCO 2022: Eight-Year Survival Rates by Baseline Prognostic Groups in Patients with mHSPC: An Analysis from the ECOG-ACRIN 3805 (CHAARTED) Trial

ASCO 2022: Gene-by-Gene Analysis in the MAGNITUDE Study of Niraparib with Abiraterone Acetate and Prednisone in Patients with mCRPC and HRR Gene Alterations

ASCO 2022: PSMA PET Tumor-to-Salivary Glands Ratio (PSG Score) to Predict Response to Lu-177 PSMA Radioligand Therapy: An International Multicenter Retrospective Study

ASCO 2022: Local and Focal: What’s Next in Salvage Therapy? - Discussion

ASCO 2022: Cohort Study of Patients With Oligorecurrent Prostate Cancer: Oncological Outcomes of Patients Treated With Salvage Lymph Node Dissection via PSMA Radioguided Surgery

ASCO 2022: Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis

1
2
3
4
5
6
7
8